PHIO PHARMACEUTICALS
Phio Pharmaceuticals is a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA) therapeutic platform. The company's discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets or to be used in immunotherapy following intratumoral injection. It aims to maximize the power of ita sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer and to make tumors more susceptible to such attacks, and ultimately provide patients battling cancers with a new treatment option that goes beyond current treatment modalities.
PHIO PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical
Founded:
2011-01-01
Address:
Worcester, Massachusetts, United States
Country:
United States
Website Url:
http://www.phiopharma.com
Total Employee:
11+
Status:
Active
Contact:
5083665877
Total Funding:
87.04 M USD
Technology used in webpage:
IPhone / Mobile Compatible Domain Not Resolving IPv6 Nginx 1.14 Akamai Hosted Verizon Verizon FIOS
Similar Organizations
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Board_member
2017-05-01
Current Employees Featured
Craig Mello Founder @ Phio Pharmaceuticals
Founder
Michael Czech Founder @ Phio Pharmaceuticals
Founder
Robert J. Bitterman Director @ Phio Pharmaceuticals
Director
Geert Cauwenbergh President and Chief Executive Officer @ Phio Pharmaceuticals
President and Chief Executive Officer
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-10-12 | MirImmune | MirImmune acquired by Phio Pharmaceuticals | N/A |
| 2011-03-31 | Apthera | Apthera acquired by Phio Pharmaceuticals | N/A |
Investors List
OPKO Health
OPKO Health investment in Post-IPO Equity - Phio Pharmaceuticals
Lincoln Park Capital Fund
Lincoln Park Capital Fund investment in Post-IPO Equity - Phio Pharmaceuticals
Official Site Inspections
http://www.phiopharma.com Semrush global rank: 4.96 M Semrush visits lastest month: 1.71 K
- Host name: 151.101.194.159
- IP address: 151.101.194.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Phio Pharmaceuticals"
Home - Phio Pharmaceuticals
Nov 19, 2024 · We’re a clinical stage biotech co-founded by the Nobel scientist who discovered RNA interference. Our proprietary INTASYL® technology is a platform for self-delivering RNAi …See details»
About us - Phio Pharmaceuticals
Phio’s founders opened up a whole new field of biology, revolutionizing the way scientists think about precision medicine. Today we continue that vision in the development of INTASYL®, our …See details»
Governance - Phio Pharmaceuticals
Stay up to date on news and investor alerts. Sign up now. © 2024 Phio PharmaceuticalsSee details»
Phio Pharmaceuticals - Wikipedia
Phio Pharmaceuticals Inc. is a US biotechnology company focused on the field of siRNA. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. See details»
Phio Pharmaceuticals Corp. | LinkedIn
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is...See details»
Phio Pharmaceuticals Corp. (PHIO) Company Profile & Facts
See the company profile for Phio Pharmaceuticals Corp. (PHIO) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Phio Pharmaceuticals (fka RXi Pharmaceuticals) | VentureRadar
Website: https://phiopharma.com/ Develops immuno-oncology therapeutics using a self-delivering RNAi platform, aiming to silence tumor-induced immune suppression and provide powerful …See details»
Phio Pharmaceuticals - Crunchbase Company Profile & Funding
Phio Pharmaceuticals is a biotechnology company specializing in the application of RNAi therapies in immuno-oncology. Its proprietary INTASYL technology is a platform for self …See details»
Phio Pharmaceuticals Appoints Robert Bitterman as President and …
Feb 22, 2023 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells …See details»
Phio Pharmaceuticals Announces Completion of Enrollment in …
Nov 19, 2024 · Marlborough, Massachusetts– (Newsfile Corp. – November 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring …See details»
Phio Pharmaceuticals Corp. (PHIO) Company Profile & Overview
2 days ago · Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. Company profile for Phio Pharmaceuticals Corp. (PHIO) with a description, list …See details»
Phio Pharmaceuticals - Overview, News & Similar companies
Phio Pharmaceuticals contact info: Phone number: (508) 767-3861 Website: www.phiopharma.com What does Phio Pharmaceuticals do? Phio Pharmaceuticals Inc. is a …See details»
Phio Pharmaceuticals - PitchBook
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more …See details»
PHIO Stock Price Quote | Morningstar
Oct 25, 2024 · Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune …See details»
Phio Pharmaceuticals Reports 2023 Year End Financial Results and ...
Apr 2, 2024 · In 2023, we made substantial progress as a focused drug development organization. In April, we submitted our first IND to the U.S. Food and Drug Administration …See details»
Phio Pharmaceuticals Corp. | Insights
RXi Pharmaceuticals Corp.was humming along in early 2017, developing clinical candidates for dermatology and ophthalmology with its self-delivering RNA-interference (sd-rxRNA) …See details»
Phio Pharmaceuticals Corp. (PHIO) - Stock Analysis
6 days ago · Get a real-time Phio Pharmaceuticals Corp. (PHIO) stock price quote with breaking news, financials, statistics, charts and more.See details»
Investors - Phio Pharmaceuticals
6 days ago · Phio Pharmaceuticals is a clinical stage biotechnology company co-founded by the scientist who was awarded the Nobel prize in 2006 for his discovery of RNAi. RNAi is precision …See details»
Phio Pharmaceuticals Corp. (PHIO) Stock Price, News, Quote
Find the latest Phio Pharmaceuticals Corp. (PHIO) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Phio Pharmaceuticals Reports Q1 2024 Results and Provides …
MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA …See details»